Cell Reprogramming in Hematopoiesis and Immunity. @LuWcmm @Lund_Stem @lunduniversity. Tweets by Filipe Pereira (signed FP) and Malavika Nair (for CFP lab).
1/4 We are recruiting! Our lab was awarded a PhD grant from @scilifelab Data-driven Life Science (DDLS) Research School for the project “A virtual cellular reprogramming screening platform”.
#DataDrivenLifeScience#CellReprogramming
4/4 ⭐️The framework is broadly adaptable, making it applicable across reprogramming systems and boosting accessibility to everyone aiming to seize the potential of direct reprogramming to generate therapeutic cell types.
1/4 Our new protocol paper is out in STAR Protocols!🎉✨
We outline how to identify transcription factor (TFs) networks for immune cell reprogramming.
Read full paper here: https://t.co/0XwXwbWrtN
3/4 The workflow includes lentiviral production, arrayed library transduction, reprogramming, cell purification, library preparation, sequencing, a downstream analysis pipeline, with quality control and troubleshooting guidance throughout.
2/2 This event will bring together scientists, clinicians, & biotech leaders to discuss present & future of immune engineering & immunotherapy. The expanding field of in vivo cell engineering will have a special focus. Save the date & join us!
More info: https://t.co/PN2zqPndJD
1/2 If you didn’t have an exciting scientific event planned for the Fall, you do now! We are thrilled to announce the Immunity by Design: In VivoImmune Cell Engineering Conference, taking place in Lund 22-23 October 2026.
#ImmuneEngineering#Immunotherapy#BiotechIndustry
🔬 Lund University is hiring 3 Assistant Professors in cancer immunotherapy, immunotechnology & immune cell engineering!
✅ Start-up package | tenure track | world-class infrastructure
📅Deadlines: 26 May & 10 June 2026
🎥https://t.co/IN6dEKKptZ
Apply links 👇
Position 3:
Immunotechnology with focus on Cancer Immunotherapy - bridging cutting-edge antibody technology and cellular therapies at the Department of Immunotechnology (LTH), within the L2CancerBridge programme.
👉 Apply: https://t.co/SHwoTn86Zb
3/3 Tenure-track position with a clear path to promotion and a substantial start-up package.
Apply by 10 June 2026.
Details here: https://t.co/6WLGkPK447
Know someone who fits? Please share with your network!✨
1/1 We are recruiting an Assistant Professor in Immuno-oncology and Immune Cell Engineering to join the newly established Division of Immuno-Oncology at Lund University!
2/3 Join us if you have a strong track record & are ready to build your own research programme in areas like:
– In vivo immune engineering
– Next-gen cell & gene therapies (CAR-T, CAR-NK)
– Synthetic immunology & CRISPR/TF screening
– Delivery systems for in situ cell engineering
4/4 We greatly appreciate SciLifeLab’s support in advancing computational immune reprogramming! If you’re excited about computational biology, single‑cell data, and modelling immune cell identity, this is a fantastic opportunity to join us.
Apply here: https://t.co/DnQbI517jY
1/4 We are recruiting! Our lab was awarded a PhD grant from @scilifelab Data-driven Life Science (DDLS) Research School for the project “A virtual cellular reprogramming screening platform”.
#DataDrivenLifeScience#CellReprogramming
3/4 Within the DDLS Research School, the recruited PhD student will analyze highly multiplexed REPROcode datasets with mathematical modelling to reveal transcription factors combinations that drive immune cell identity.
3/3 This work will define the structural and temporal barriers that are limiting PIB reprogramming efficiency to enable efficacy across tumors and successful clinical translation. Bravo Sandhya!
For more info see: https://t.co/Cg7SLcBiUE
1/3 Huge congrats to our team member Sandhya Malla @mal71056, who was awarded a Postdoctoral Fellowship by @Cancerfonden with her project “Decoding The Regulatory Grammar of Transcription Factor-Mediated Immune Reprogramming”!
2/3 Despite the therapeutic promise of tumor-to-dendritic cell reprogramming by PU.1, IRF8 and BATF3 (PIB) overexpression, reprogramming efficiency is variable across tumors. Sandhya will address this by decoding the nucleosomal structure and temporal dynamics of PIB activity.